Biomarkers Consortium

The study is part of the Biomarkers Consortium, and will include the collection of DNA samples for future genomics research into ASD.

NEW YORK (GenomeWeb) – Proteomics firm Caprion this week launched its CNS ProteoCarta panel for the study of central nervous system diseases.

Teams led by researchers at George Mason University have published a pair of studies exploring protein signaling in breast and colon cancer that could offer new insights into treatments for the diseases.

Technology developed by Lance Liotta and Emanuel Petricoin will be used to find and identify biomarkers for evaluating new investigational therapies for the neoadjuvant-drug study.

The I-SPY effort will conduct pharmacogenomics-focused clinical trials for breast cancer drugs using Agendia's tests.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.